Eileen Koutnik-Fotopoulos

Authored Items

ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year

July 2017, Vol 7, No 7 - ASCO Annual Report

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. This surge of progress using cancer immunotherapy has led the American Society of Clinical Oncology (ASCO) to name “Immunotherapy 2.0” as its cancer advance of the year for a second year in a row. [ Read More ]